請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/25034
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 陳秀熙,許銘能 | |
dc.contributor.author | Heng-Chia Pan | en |
dc.contributor.author | 潘恆嘉 | zh_TW |
dc.date.accessioned | 2021-06-08T06:00:43Z | - |
dc.date.copyright | 2007-08-08 | |
dc.date.issued | 2007 | |
dc.date.submitted | 2007-07-28 | |
dc.identifier.citation | 1. WHO. World Health Organization Tobacco Free Initiative.
2. 行政院衛生署國民健康局. 菸害防制. 3. 台灣三個族群在抽菸飲酒及嚼食檳榔習慣異質性之探討. 壢新醫院社區健康篩檢研討會: 多族群在社區常見慢性病中所扮演的角色; 2006. 4. 不同族群吸菸、飲酒及檳榔嚼食習慣盛行狀況比較: 以花蓮縣整合式篩檢參加族群為例. 花蓮縣整合式篩檢成果發表暨跨族群慢性病國際研討會; 2007. 5. 門診戒菸治療管理中心. 衛生署國民健康局門診戒菸治療管理中心九十五年期末報告 2006. 6. 陳宙珍. 門診戒菸之成效及相關因素探討 [碩士論文]. 台北市: 衛生政策與管理研究所, 臺灣大學; 2006. 7. Soemmering ST. De morbis vasorum absorbentium corporis humanai. . Frankfurt, Germany: Varrentrapp & Wenner; 1795. 8. Abbe R. Cancer of the mouth. The case against tobacco. N Y Med J. 1915;102:1-2. 9. Adler I. Primary malignant growths of the lung and bronchi. London: Longmans, Green and Co.,Ltd.; 1912. 10. Roffo AH. Krebseizeugendes Benzpyren gewonnen aus Tabakteer. Z Krebsforsch. 1939;49:588-597. 11. Cook JW, Hewett, C.L., and Hieger, I. The isolation of cancer-producing hydrocarbons from coal tar. . 1933:395-405. 12. Wynder EL, and Hoffmann, D. Tobacco and tobacco smoke. Studies in experimental tobacco carcinogenesis. New York; 1967. 13. Wynder EL, Graham EA. Landmark article May 27, 1950: Tobacco Smoking as a possible etiologic factor in bronchiogenic carcinoma. A study of six hundred and eighty-four proved cases. By Ernest L. Wynder and Evarts A. Graham. Jama. May 24-31 1985;253(20):2986-2994. 14. Doll R, Hill AB. Smoking and carcinoma of the lung; preliminary report. Br Med J. Sep 30 1950;2(4682):739-748. 15. Doll R, Hill AB. The mortality of doctors in relation to their smoking habits; a preliminary report. Br Med J. Jun 26 1954;1(4877):1451-1455. 16. Doll R, Hill AB. Lung cancer and other causes of death in relation to smoking; a second report on the mortality of British doctors. Br Med J. Nov 10 1956;2(5001):1071-1081. 17. 羅于韻. 戒菸面面觀. 基層醫學. 2005;20(10):272-278. 18. Answers.com. Smoking Cessation. 19. Huang CL, Lin HH, Wang HH. Psychometric evaluation of the Chinese version of the Fagerstrom Tolerance Questionnaire as a measure of cigarette dependence. J Adv Nurs. Sep 2006;55(5):596-603. 20. Huang CL, Lin HH, Wang HH. The psychometric properties of the Chinese version of the Fagerstrom Test for Nicotine Dependence. Addict Behav. Dec 2006;31(12):2324-2327. 21. 衛生署國民健康局. 門診戒菸治療試辦計畫教育課程基本教材; 2003. 22. 行政院衛生署國民健康局. 2002年台灣地區國民健康促進知識態度與行為調查: 行政院衛生署國民健康局; 2002. 23. Patrick DL, Cheadle A, Thompson DC, et al. The validity of self-reported smoking: a review and meta-analysis. Am J Public Health. Jul 1994;84(7):1086-1093. 24. Becona E, Vazquez FL. Self-reported smoking and measurement of expired air carbon monoxide in a clinical treatment. Psychol Rep. Aug 1998;83(1):316-318. 25. Becona E, Miguez MC. Concordance of self-reported abstinence and measurement of expired air carbon monoxide in a self-help smoking cessation treatment. Psychol Rep. Aug 2006;99(1):125-130. 26. Barrueco M, Jimenez Ruiz C, Palomo L, et al. [Veracity of smokers' reports of abstinence at smoking cessation clinics]. Arch Bronconeumol. Mar 2005;41(3):135-140. 27. Morabia A, Bernstein MS, Curtin F, et al. Validation of self-reported smoking status by simultaneous measurement of carbon monoxide and salivary thiocyanate. Prev Med. Jan 2001;32(1):82-88. 28. Fiore MC. US public health service clinical practice guideline: treating tobacco use and dependence. Respir Care. Oct 2000;45(10):1200-1262. 29. Department of Health and Human Service: The health benefits of smoking cessation: A report of the Surgeon General. Office on Smoking and Health. Washington. DC. 1990. 30. USDHHS. US Department of Health and Human Services(USDHHS), Center for Disease Control and Prevention; 2006. 31. 衛生署國民健康局. 台灣菸害防制年報-2005年 2005. 32. 黃雅慧. 國民健康局門診戒菸計畫之成本效益分析 [碩士論文]. 台北市: 衛生福利研究所, 國立陽明大學; 2004. 33. Lancaster T, Stead L. Physician advice for smoking cessation. Cochrane Database Syst Rev. 2004(4):CD000165. 34. Rice VH, Stead LF. Nursing interventions for smoking cessation. Cochrane Database Syst Rev. 2004(1):CD001188. 35. Lancaster T, Stead LF. Individual behavioural counselling for smoking cessation. Cochrane Database Syst Rev. 2005(2):CD001292. 36. Stead LF, Lancaster T. Group behaviour therapy programmes for smoking cessation. Cochrane Database Syst Rev. 2005(2):CD001007. 37. Stead LF, Perera R, Lancaster T. Telephone counselling for smoking cessation. Cochrane Database Syst Rev. 2006;3:CD002850. 38. Rigotti NA, Munafo MR, Murphy MF, et al. Interventions for smoking cessation in hospitalised patients. Cochrane Database Syst Rev. 2003(1):CD001837. 39. Sinclair HK, Bond CM, Stead LF. Community pharmacy personnel interventions for smoking cessation. Cochrane Database Syst Rev. 2004(1):CD003698. 40. Moher M, Hey K, Lancaster T. Workplace interventions for smoking cessation. Cochrane Database Syst Rev. 2005(2):CD003440. 41. Lancaster T, Stead LF. Self-help interventions for smoking cessation. Cochrane Database Syst Rev. 2005(3):CD001118. 42. Ussher M. Exercise interventions for smoking cessation. Cochrane Database Syst Rev. 2005(1):CD002295. 43. Silagy C, Lancaster T, Stead L, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2004(3):CD000146. 44. Gourlay SG, Stead LF, Benowitz NL. Clonidine for smoking cessation. Cochrane Database Syst Rev. 2004(3):CD000058. 45. Hughes J, Stead L, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev. 2004(4):CD000031. 46. White AR, Rampes H, Campbell JL. Acupuncture and related interventions for smoking cessation. Cochrane Database Syst Rev. 2006(1):CD000009. 47. Okuyemi KS, Nollen NL, Ahluwalia JS. Interventions to facilitate smoking cessation. Am Fam Physician. Jul 15 2006;74(2):262-271. 48. Monso E, Campbell J, Tonnesen P, et al. Sociodemographic predictors of success in smoking intervention. Tob Control. Jun 2001;10(2):165-169. 49. Gourlay SG, Forbes A, Marriner T, et al. Prospective study of factors predicting outcome of transdermal nicotine treatment in smoking cessation. Bmj. Oct 1 1994;309(6958):842-846. 50. Ryckman KA, Bercaw DM, Ellis MR, et al. Clinical inquiries. What predicts a successful smoking cessation attempt? J Fam Pract. Sep 2006;55(9):816-819. 51. Levy DT, Romano E, Mumford E. The relationship of smoking cessation to sociodemographic characteristics, smoking intensity, and tobacco control policies. Nicotine Tob Res. Jun 2005;7(3):387-396. 52. Gilman SE, Abrams DB, Buka SL. Socioeconomic status over the life course and stages of cigarette use: initiation, regular use, and cessation. J Epidemiol Community Health. Oct 2003;57(10):802-808. 53. Lam TH, Abdullah AS, Chan SS, et al. Adherence to nicotine replacement therapy versus quitting smoking among Chinese smokers: a preliminary investigation. Psychopharmacology (Berl). Feb 2005;177(4):400-408. 54. Fagerstrom KO, Heatherton TF, Kozlowski LT. Nicotine addiction and its assessment. Ear Nose Throat J. Nov 1990;69(11):763-765. 55. Chatkin JM, Mariante de Abreu C, Haggstram FM, et al. Abstinence rates and predictors of outcome for smoking cessation: do Brazilian smokers need special strategies? Addiction. Jun 2004;99(6):778-784. 56. Swan GE, Jack LM, Curry S, et al. Bupropion SR and counseling for smoking cessation in actual practice: predictors of outcome. Nicotine Tob Res. Dec 2003;5(6):911-921. 57. Franken FH, Pickworth WB, Epstein DH, et al. Smoking rates and topography predict adolescent smoking cessation following treatment with nicotine replacement therapy. Cancer Epidemiol Biomarkers Prev. Jan 2006;15(1):154-157. 58. Kawai H, Shibayama T, Tada A, et al. [Factors affecting the success or failure of smoking cessation using nicotine patches]. Nihon Kokyuki Gakkai Zasshi. Mar 2005;43(3):144-149. 59. Kenford SL, Fiore MC, Jorenby DE, et al. Predicting smoking cessation. Who will quit with and without the nicotine patch. Jama. Feb 23 1994;271(8):589-594. 60. Alterman AI, Gariti P, Cook TG, et al. Nicodermal patch adherence and its correlates. Drug Alcohol Depend. Jan 7 1999;53(2):159-165. 61. Raherison C, Marjary A, Valpromy B, et al. Evaluation of smoking cessation success in adults. Respir Med. Oct 2005;99(10):1303-1310. 62. Hughes JR, Novy P, Hatsukami DK, et al. Efficacy of nicotine patch in smokers with a history of alcoholism. Alcohol Clin Exp Res. Jun 2003;27(6):946-954. 63. Cooper TV, DeBon MW, Stockton M, et al. Correlates of adherence with transdermal nicotine. Addict Behav. Nov 2004;29(8):1565-1578. 64. Patterson F, Jepson C, Kaufmann V, et al. Predictors of attendance in a randomized clinical trial of nicotine replacement therapy with behavioral counseling. Drug Alcohol Depend. Nov 24 2003;72(2):123-131. 65. Orleans CT, Resch N, Noll E, et al. Use of transdermal nicotine in a state-level prescription plan for the elderly. A first look at 'real-world' patch users. Jama. Feb 23 1994;271(8):601-607. 66. Wiggers LC, Smets EM, Oort FJ, et al. Adherence to nicotine replacement patch therapy in cardiovascular patients. Int J Behav Med. 2006;13(1):79-88. 67. Fiore MC, Smith SS, Jorenby DE, et al. The effectiveness of the nicotine patch for smoking cessation. A meta-analysis. Jama. Jun 22-29 1994;271(24):1940-1947. 68. Cummings KM, Biernbaum RM, Zevon MA, et al. Use and effectiveness of transdermal nicotine in primary care settings. Arch Fam Med. Aug 1994;3(8):682-689. 69. WHO. Disease-specific reviews: Tobacco smoking cessation. In World Health Report Organization(Ed.), Adherence to long-term therapies: evidence for action. 2003. 70. Fornai E, Desideri M, Pistelli F, et al. Smoking reduction in smokers compliant to a smoking cessation trial with nicotine patch. Monaldi Arch Chest Dis. Feb 2001;56(1):5-10. 71. Solomon LJ, Scharoun GM, Flynn BS, et al. Free nicotine patches plus proactive telephone peer support to help low-income women stop smoking. Prev Med. Jul 2000;31(1):68-74. 72. Killen JD, Fortmann SP, Davis L, et al. Do heavy smokers benefit from higher dose nicotine patch therapy? Exp Clin Psychopharmacol. Aug 1999;7(3):226-233. 73. Sachs DP, Sawe U, Leischow SJ. Effectiveness of a 16-hour transdermal nicotine patch in a medical practice setting, without intensive group counseling. Arch Intern Med. Aug 23 1993;153(16):1881-1890. 74. Russell MA, Stapleton JA, Feyerabend C, et al. Targeting heavy smokers in general practice: randomised controlled trial of transdermal nicotine patches. Bmj. May 15 1993;306(6888):1308-1312. 75. 王建楠 門診戒菸治療服務成效之綜合分析. 台灣醫界 Taiwan Medical Journal. 2007;50(2):25-28. 76. 薛光傑. 某醫學中心門診戒菸成效. 台灣家醫誌. 2006;16:1-12. 77. Russell MA, Wilson C, Feyerabend C, et al. Effect of nicotine chewing gum on smoking behaviour and as an aid to cigarette withdrawal. Br Med J. Aug 14 1976;2(6032):391-393. 78. Henningfield JE, Radzius A, Cooper TM, et al. Drinking coffee and carbonated beverages blocks absorption of nicotine from nicotine polacrilex gum. Jama. Sep 26 1990;264(12):1560-1564. 79. Hughes JR, Hatsukami DK, Skoog KP. Physical dependence on nicotine in gum. A placebo substitution trial. Jama. Jun 20 1986;255(23):3277-3279. 80. D'Orlando KJ, Fox BS. Tolerability and pharmacokinetics of single and repeated doses of nicotine with The Straw, a novel nicotine replacement product. Nicotine Tob Res. Feb 2004;6(1):63-70. 81. Park CR, Munday DL. Development and evaluation of a biphasic buccal adhesive tablet for nicotine replacement therapy. Int J Pharm. Apr 26 2002;237(1-2):215-226. 82. Etter JF, Stapleton JA. Nicotine replacement therapy for long-term smoking cessation: a meta-analysis. Tob Control. Aug 2006;15(4):280-285. 83. Etter JF, Laszlo E. Postintervention effect of nicotine replacement therapy for smoking reduction: a randomized trial with a 5-year follow-up. J Clin Psychopharmacol. Apr 2007;27(2):151-155. 84. Prochaska JO, DiClemente CC. Stages and processes of self-change of smoking: toward an integrative model of change. J Consult Clin Psychol. Jun 1983;51(3):390-395. 85. Prochaska JO, DiClemente CC. Stages of change in the modification of problem behaviors. Prog Behav Modif. 1992;28:183-218. 86. van Sluijs EM, van Poppel MN, van Mechelen W. Stage-based lifestyle interventions in primary care: are they effective? Am J Prev Med. May 2004;26(4):330-343. 87. Riemsma RP, Pattenden J, Bridle C, et al. Systematic review of the effectiveness of stage based interventions to promote smoking cessation. Bmj. May 31 2003;326(7400):1175-1177. 88. Spencer L, Pagell F, Hallion ME, et al. Applying the transtheoretical model to tobacco cessation and prevention: a review of literature. Am J Health Promot. Sep-Oct 2002;17(1):7-71. 89. O'Hea EL, Wood KB, Brantley PJ. The transtheoretical model: gender differences across 3 health behaviors. Am J Health Behav. Nov-Dec 2003;27(6):645-656. 90. Hurt RD, Eberman KM, Croghan IT, et al. Nicotine dependence treatment during inpatient treatment for other addictions: a prospective intervention trial. Alcohol Clin Exp Res. Aug 1994;18(4):867-872. 91. Town GI, Fraser P, Graham S, et al. Establishment of a smoking cessation programme in primary and secondary care in Canterbury. N Z Med J. Apr 14 2000;113(1107):117-119. 92. Croghan IT, Offord KP, Evans RW, et al. Cost-effectiveness of treating nicotine dependence: the Mayo Clinic experience. Mayo Clin Proc. Oct 1997;72(10):917-924. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/25034 | - |
dc.description.abstract | 研究目的
有關台灣地區戒菸行為模式,過去研究雖多有探討,但是鮮少對不同階段之間提出新的解釋模型以及影響因子之探討。本研究目的有二:(1)參考跨理論行為模式,提出適合台灣地區戒菸門診中多階段戒菸模型(持續抽菸、猶豫戒菸及戒菸成功),(2)探討戒菸族群在菸癮戒除過程中,由抽菸期轉移至心存猶豫以及戒菸成功等階段的影響因子。 材料與方法 本研究所使用的資料主要來自國民健康局自2003年起各縣市所推動的門診戒菸計劃,此計劃透過醫療院所以及社區衛生所辦理門診戒菸來協助民眾戒菸,對於18歲以上之成人,尼古丁成癮度達4分以上或平均一天吸10支菸以上,願意接受簽約之醫療院所所提供之戒菸治療,共收案2,791人。本研究將戒菸過程定義為三個分期,分別為抽菸期(Smoking Phase)、猶豫期(Hesitation Phase)及戒菸成功期(Quitting Smoking)。根據本研究架構所定義的多階段分期可知本研究之依變項包括(1)戒菸猶豫期以及(2)戒菸成功。在自變項部分,我們利用門診戒菸記錄表與電訪所收集之資料,作為本研究各階段相關因子的定義,概分為個案戒菸經驗、個案健康狀況、個案菸癮相關因子、周遭親友疾病經驗,與自覺健康與效益等因素。由於門診戒菸記錄表並未追蹤戒菸成果,本結果設計一問卷進行電話訪談收集民眾戒菸成果、自覺健康、親友疾病經驗、對門診戒菸的記憶以及門診戒菸的效益訊息。 在資料分析方面,本研究利用羅吉斯迴歸模式(Logistic Regression Model)分析影響是否參加第二次以上的戒菸門診及是否戒菸成功兩種二元事件的各別影響因子,並利用比例危險迴歸模式(Proportional Hazards Regression Model)分析在考慮最後一次接受戒菸門診到戒菸成功時所花費時間的影響因子,最後利用多階段模式(Multi-state Model)量化個人在抽菸與意圖戒菸之間行為的轉移及兩種狀態其分別進展至戒菸成功的轉移率。 結果 本研究之研究族群共2,791人,分別來自基隆市(n=125人)、台北縣(n=1,124人)、台南縣(n=1,308人)、連江縣(馬祖)(n=123人)及台東縣(n=111人)等五個縣市在2004年至2006年間參加戒菸門診的民眾,其中主要以台北縣及台南縣為主,各佔40.3%及46.9%。 在影響戒菸猶豫期之相關因子方面包括有個案年齡 (OR=1.01, 95% CI: 1.00-1.01, p=0.0009)、是否罹患過肝病 (OR=1.64, 95% CI: 1.09-2.47, p=0.0189)、在禁菸區會感到難受 (OR=1.21, 95% CI: 1.03-1.41, p=0.0172),以及戒菸門診提供單位 (OR=1.67, 95% CI: 1.26-2.21, p=0.0004)。 影響戒菸成功相關因子有越年邁者越容易戒菸成功 (OR=1.05, 95% CI=1.03-1.08, P<.0001),菸齡在15(含)年以下者相對戒菸成功比較高 (OR=6.03, 95% CI=2.27-16.04, P=0.0003),自覺健康較同年齡者佳者,有較高的相對戒菸成功比 (OR=7.14, 95% CI=3.22-15.83, P<.0001),自己罹患有糖尿病者,相對戒菸勝算比為3.02 (95% CI=1.08-8.44, P<0.0349),因自己有健康問題而參加門診戒菸者,相對戒菸成功比為2.23倍,(95% CI=0.99-5.00, P<0.0520)。 以比例危險迴歸模式進行多變項分析,其中菸齡的解釋力最大,菸齡小於15年者其戒菸速率為大於者之4.45倍(95%信賴區間:1.93-10.29)。再者為本身為糖尿病患者,其戒菸速率為非糖尿病患者之2.71倍(95%信賴區間:1.25-5.89)。接著為自覺健康狀態,其中自覺健康比較好者的戒菸速率為自覺健康比較差者的2.34倍(95%信賴區間:1.53-3.58),覺得沒有差者約為自覺健康比較差者的四成(95%信賴區間:0.24-0.57)。當嚴重生病、臥病在床時不會抽菸者為仍會抽菸者之1.89倍(95%信賴區間:1.20-2.97)。年齡每增加一歲其戒菸成功速率增為1.04倍(95%信賴區間:1.02-1.06)。 利用連續時間馬可夫模式估計個案在抽菸期、猶豫期及戒菸期之間,估計結果顯示個案從抽菸期轉變到猶豫期的轉移速率約為每天1.85次(95%信賴區間:0-7.24),由猶豫期返回抽菸期的速率則為每天0.64次(95%信賴區間:0-2.50),由抽菸期和猶豫期分別進展至戒菸期的轉移速率則分別為每天2.69 | zh_TW |
dc.description.abstract | Objectives:
Despite a number of studies addressing smoking cessation outpatient service (SCOS) in Taiwan, very few studies have been conducted to address factors associated with different stages of smoking behaviour change or to propose a new model to accommodate such a multi-state process. The present study aimed (1) to propose a new stage of change model to interpret the behaviour of outpatient smoking cessation in Taiwan and (2) to assess relevant factors associated with different behaviour change states, from smoking phase either to hesitation phase or to quitting smoking. Methods: The study subjects (n=2,791) were enrolled from the 2004-2006 SCOS in five Taiwan Counties and a telephone interview design. By defining state of change with three phases related to smoking quitting process, including current smoking phase, hesitation phase, and quitting smoking phase were proposed. Independent variables used in our analyses included (1) basic information of smokers with their quitting smoking experiences (2) personal health status (diseases) (3) nicotine dependent factors (4) diseases histories of their friends and relatives (5) perceived health status. We used logistic regression models to elucidate the effects of relevant factors on whether to have more than two visits of SCOS or whether to quit smoking successfully respectively. The proportional hazards regression model was used to analyze the effects of relevant risk factors on time to smoking cessation. Finally, we applied the multi-state models to quantify the transitions between smoking, hesitation to quit, and quitting from the two states. Results: Factors associated with hesitation phase include age, personal diseases with liver diseases, feeling discomfort in the non-smoking area, those who received the smoking cessation outpatient service from the public health centers, were identified as significant predictors. Factors associated with quitting smoking included age, smoking age, perceiving better health than peers, having diabetes mellitus, and attending the smoking cessation clinic due to personal perceived illness. Results of proportional hazards regression model found those who were more likely to quit smoking were elderly, short duration of smoking age, having diabetes mellitus, perceiving better health than peers, or stopping smoking when being ill in bed. In the continuous-time Markov model, the transition rate from smoking to hesitation phase was estimated as 1.85 per day (95% CI: 0-7.24), and the estimated regression rate from hesitation phase to smoking was 0.64 per day (95% CI: 0-2.50). The daily successful quitting rates from smoking and from hesitation phase in the previous time were estimated as 2.69x10-4 (95% CI: 1.87 x10-4-3.50 x10-4) and 2.44 x10-4 (95% CI: 1.18 x10-4-3.71 x10-4), respectively. In terms of annual quitting rates, the figures were 0.0982 (95% CI: 0.0684-0.1279) and 0.0891 (95% CI: 0.0432-0.1353), respectively. Those perceived healthier has 3.18 times higher quitting rate compared with those perceived worse or equal health. The corresponding figure from hesitation phase was 16.27 (95% CI: 3.74-71.28). Heavy smokers with desire of smoking which having serious diseases had 1.41 (95% CI: 0.98-2.02) times higher transition rate from smoking phase to hesitation phase. The corresponding figure for the regression from hesitation phase back to smoking phase was 1.64 (95% CI: 1.15-2.35). Conclusions: We proposed a new model of multi-state stochastic process for quitting smoking for Taiwanese males who using smoking cessation outpatient service. This multi-state model included smoking phase, hesitation phase and quitting smoking. Using different regression models, the results found those who were more likely to quit smoking were elderly, perceiving better health than peers, having diabetes mellitus, or stopping smoking when being ill in bed. Such a novel multi-state model may be applied to aid men in any phases to quit smoking. | en |
dc.description.provenance | Made available in DSpace on 2021-06-08T06:00:43Z (GMT). No. of bitstreams: 1 ntu-96-R94846012-1.pdf: 783094 bytes, checksum: a95bf3b2ce588dc8f9220eaa0a47bb16 (MD5) Previous issue date: 2007 | en |
dc.description.tableofcontents | 誌謝
中文摘要 英文摘要 第一章 緒論……………………………………………………… 1 第一節 研究背景與動…………………………………………… 1 1.1.1 抽菸之盛行率與對健康的危害…………………………. 1 1.1.2 國內門診戒菸實………………………………………… 1 第二節 研究目的………………………………………………….3 第二章 文獻探討………………………………………………… 4 第一節 菸害防制簡史………………………………………… 4 第二節 慢性抽菸成癮與戒除行為……………………………… 5 2.2.1 抽菸成癮…………………………………………………… 5 2.2.2 抽菸行為的定義…………………………………………… 7 2.2.3 抽菸行為狀態的測量……………………………………… 7 2.2.4 戒菸的定義………………………………………………… 8 2.2.5 戒菸之盛行率與戒菸之益處……………………………… 8 第三節 台灣菸害防制計畫……………………………………… 9 2.3.1 菸害防制法………………………………………………… 9 2.3.2 無菸校園……………………………………………………10 2.3.3 創造無菸環境,降低二手菸暴露…………………………10 2.3.4 國民健康局門診戒菸治療計畫………………………… 10 2.3.5 國民健康局門診戒菸治療計畫之成本效益分析…………12 第四節 戒菸方法與成效…………………………………………13 2.4.1 菸害防制的實證方法………………………………………13 2.4.2 戒菸成效之相關因子………………………………………15 2.4.3 尼古丁替代療法順從性……………………………………16 2.4.4 國內戒菸成效相關之研究…………………………………18 第五節 尼古丁替代療法…………………………………………19 2.5.1 尼古丁替代藥物之發明……………………………………19 2.5.2 尼古丁替代療法……………………………………………20 2.5.3 尼古丁替代療法之治療效果………………………………21 第六節 門診戒菸利用之理論架構………………………………23 2.6.1 跨理論模式…………………………………………………23 2.6.2 行為改變模式理論於戒菸上之應用………………………25 第三章 材料與方法………………………………………………26 第一節 戒菸過程模式……………………………………………26 第二節 目標族群…………………………………………………26 3.2.1 戒菸猶豫期研究族群………………………………………27 3.2.2 戒菸成功研究族群…………………………………………27 3.2.3 結合社區整合式篩檢資料庫進行戒菸成功相關因子探討28 第三節 變項定義…………………………………………………30 3.3.1 依變項………………………………………………………30 3.3.2 自變項………………………………………………………30 第四節 資料收集…………………………………………………31 第五節 尼古丁替代療法戒菸成效之統合分析…………………32 3.5.1 統計分析方法………………………………………………32 第六節 戒菸多階段模型建構……………………………………35 第七節 統計方法…………………………………………………36 3.7.1 羅吉斯迴歸模式……………………………………………36 3.7.2 比例危險迴歸模式…………………………………………36 3.7.3 多階段模式…………………………………………………37 第四章 結果………………………………………………………40 第一節 基本資料描述……………………………………………40 第二節 統合分析結果……………………………………………47 第三節 影響戒菸猶豫期之相關因子(羅吉斯回歸分析)………52 第四節 影響戒菸成功相關因子…………………………………59 第五節 影響戒菸成功相關因子之比例危險迴歸模式分析……69 第六節 多階段(抽菸期-猶豫期-戒菸期)模式分析結果…76 第七節 合併整合式篩檢之結果…………………………………81 第五章 討論………………………………………………………83 第一節 主要發現…………………………………………………83 第二節 多階段改變理論的革新…………………………………84 第三節 中西菸癮戒除行為與認知………………………………85 第四節 與國外文獻的比較………………………………………86 第五節 研究方法之新穎…………………………………………88 第六節 研究限制與顧慮…………………………………………89 第六章 結論………………………………………………………91 參考文獻……………………………………………………………92 圖表目錄 圖目錄 圖3-2-3 研究族群…………………………………………………29 圖3-5-1 尼古丁輔助戒菸之隨機效應分析模式…………………33 圖3-5-2 考慮觀察時間因素之NRT之隨機效應羅吉斯迴歸模式 34 圖3-6-1 三階段行為模型…………………………………………35 圖4-2-3 尼古丁輔助戒菸隨機分派試驗統合分析………………51 表目錄 表2-2-1 Fagerström尼古丁依賴測試表…………………………6 表2-3-4 目前台灣已引進或常用戒菸治療藥物…………………12 表2-4-1 戒菸之實證方法…………………………………………14 表4-1-1 研究族群來源地區(縣市)及使用門診時間(年份)……40 表4-1-2 研究族群戒菸經驗分佈…………………………………42 表4-1-3 研究族群疾病經驗分佈…………………………………44 表4-1-4 研究族群菸癮相關因子分佈……………………………46 表4-2-1 戒菸尼古丁輔助介入隨機分派結果之文獻整理………48 表4-2-2 統合分析危險對比值……………………………………49 表4-2-3 考慮觀察時間對於尼古丁輔助戒菸隨機分派試驗統合分析…… 50 表4-3-1 羅吉斯回歸分析猶豫期相關因子單變項分析(戒菸經驗)………. 53 表4-3-2 羅吉斯回歸分析猶豫期相關因子單變項分析(個人疾病經驗)… 55 表4-3-3 羅吉斯回歸分析猶豫期相關因子單變項分析(菸癮相關因子)… 57 表4-3-4 羅吉斯回歸分析菸猶豫期相關因子多變項分析………58 表4-4-1 北縣南縣戒菸成功相關因子單變項分析(戒菸經驗)………… 60 表4-4-2 北縣南縣戒菸成功相關因子單變項分析(個人疾病經驗)……… 62 表4-4-3 北縣南縣戒菸成功相關因子單變項分析(個人菸癮相關因子)… 64 表4-4-4 北縣南縣戒菸成功相關因子單變項分析(親友得病經驗)………. 66 表4-4-5 北縣南縣戒菸成功相關因子單變項分析(自覺健康效益)……… 67 表4-4-6 北縣南縣戒菸成功相關因子多變項分析………………68 表4-5-1 比例危險迴歸模式進行兩縣族群戒菸成功速率之 單變項分析 (戒菸經驗)……………………………………………69 表4-5-2 比例危險迴歸模式進行兩縣族群戒菸成功速率之 單變項分析 (個人疾病經驗)………………………………………70 表4-5-3 比例危險迴歸模式進行兩縣族群戒菸成功速率之 單變項分析 (個人菸癮相關因子)…………………………………71 表4-5-4 比例危險迴歸模式進行兩縣族群戒菸成功速率之 單變項分析 (親友健康經驗/健康信念模型(意感威脅)因子)… 72 表4-5-5 比例危險迴歸模式進行兩縣族群戒菸成功速率之 單變項分析 (自覺健康效益)………………………………………73 表4-5-6 比例危險迴歸模式進行兩縣族群戒菸成功速率之多變項分析… 75 表4-6-1 應用多階段連續時間馬可夫模式於 戒菸研究階段間轉移速率估計結果……………………………… 76 表4-6-2 應用多階段間斷時間馬可夫模式於 戒菸研究階段間轉移機率估計結果……………………………… 78 表4-6-3 影響多階段間斷時間馬可夫模式於 戒菸機率之相關因子分析………………………………………… 79 表4-6-4 影響多階段間斷時間馬可夫模式於 抽菸期及猶豫期間轉移機率之相關因子分析…………………… 80 表4-7-1 結合整篩後戒菸成功相關因素多變項羅吉斯廻歸分析結果…… 82 | |
dc.language.iso | zh-TW | |
dc.title | 台灣地區男性戒菸的多階段隨機模型之探討 | zh_TW |
dc.title | Multistate Stochastic Process for Quitting Smoking for Taiwanese Males | en |
dc.type | Thesis | |
dc.date.schoolyear | 95-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 陸玓玲,張淑惠 | |
dc.subject.keyword | 戒菸,尼古丁替代療法,門診戒菸,菸害防制,跨理論行為模式,多階段模型, | zh_TW |
dc.subject.keyword | Smoking cessation,Nicotine replacement therapy,Smoking cessation outpatient service,Tobacco control,Transtheoretical model,Multi-state mode, | en |
dc.relation.page | 99 | |
dc.rights.note | 未授權 | |
dc.date.accepted | 2007-07-30 | |
dc.contributor.author-college | 公共衛生學院 | zh_TW |
dc.contributor.author-dept | 預防醫學研究所 | zh_TW |
顯示於系所單位: | 流行病學與預防醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-96-1.pdf 目前未授權公開取用 | 764.74 kB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。